Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Yangxinshi Tablets in Coronary Heart Disease with Cardiac Dysfunction
NCT07110415Phase 4Recruiting
- Sponsor
- Shanghai Pharmaceuticals Group Qingdao Growful Pharmaceutical
- Start
- Nov 2025
- Primary completion
- Aug 2030
- Countries
- 1
01
Overview
A Phase 4 trial of yangxinshi in coronary heart disease (CHD), Cardiac dysfunction, sponsored by Shanghai Pharmaceuticals Group Qingdao Growful Pharmaceutical. Started Nov 2025; status: recruiting.
02
Drugs
yangxinshi
03
Conditions
coronary heart disease (CHD)Cardiac dysfunction
Beyond the preview
Go deeper on NCT07110415.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07110415.